182 related articles for article (PubMed ID: 34593036)
1. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
[TBL] [Abstract][Full Text] [Related]
2. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
3. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
[TBL] [Abstract][Full Text] [Related]
4. Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
Bakouni H; Haquet L; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
J Addict Med; 2024 Mar-Apr 01; 18(2):167-173. PubMed ID: 38258865
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
6. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.
Zhu Y; Evans EA; Mooney LJ; Saxon AJ; Kelleghan A; Yoo C; Hser YI
J Neuroimmune Pharmacol; 2018 Dec; 13(4):488-497. PubMed ID: 30094695
[TBL] [Abstract][Full Text] [Related]
7. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
8. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.
Thakrar AP; Uritsky TJ; Christopher C; Winston A; Ronning K; Sigueza AL; Caputo A; McFadden R; Olenik JM; Perrone J; Delgado MK; Lowenstein M; Compton P
Addict Sci Clin Pract; 2023 Feb; 18(1):13. PubMed ID: 36829242
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone.
Kazi I; Chenoweth MJ; Jutras-Aswad D; Ahamad K; Socias ME; Le Foll B; Tyndale RF
Clin Pharmacol Ther; 2024 Mar; 115(3):506-514. PubMed ID: 38009933
[TBL] [Abstract][Full Text] [Related]
10. Patient Satisfaction With Standard Methadone and Flexible Buprenorphine/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial.
Hassan AN; Bozinoff N; Jutras-Aswad D; Socias ME; Stewart SH; Lim R; Le Foll B;
J Addict Med; 2023 Jan-Feb 01; 17(1):e49-e56. PubMed ID: 35916430
[TBL] [Abstract][Full Text] [Related]
11. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
[TBL] [Abstract][Full Text] [Related]
12. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
[TBL] [Abstract][Full Text] [Related]
13. Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Baxley C; Borsari B; Reavis JV; Manuel JK; Herbst E; Becker W; Pennington D; Batki SL; Seal K
Addict Behav; 2023 Apr; 139():107589. PubMed ID: 36565531
[TBL] [Abstract][Full Text] [Related]
14. A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy.
Schmidt RA; Everett K; Perez-Brumer A; Strike C; Rush B; Gomes T
Addiction; 2024 Jun; 119(6):1111-1122. PubMed ID: 38476027
[TBL] [Abstract][Full Text] [Related]
15. Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment.
Luo SX; Feaster DJ; Liu Y; Balise RR; Hu MC; Bouzoubaa L; Odom GJ; Brandt L; Pan Y; Hser YI; VanVeldhuisen P; Castillo F; Calderon AR; Rotrosen J; Saxon AJ; Weiss RD; Wall M; Nunes EV
JAMA Psychiatry; 2024 Jan; 81(1):45-56. PubMed ID: 37792357
[TBL] [Abstract][Full Text] [Related]
16. Mediating effect of craving on the impact of buprenorphine/naloxone and methadone treatment on opioid use: Results from a randomized controlled trial.
McAnulty C; Bastien G; Ledjiar O; Eugenia Socias M; Le Foll B; Lim R; Jutras-Aswad D;
Addict Behav; 2024 Jul; 154():108023. PubMed ID: 38579594
[TBL] [Abstract][Full Text] [Related]
17. Variation in Use of Medications for Opioid Use Disorder in Critically Ill Patients Across the United States.
Feeney ME; Law AC; Walkey AJ; Bosch NA
Crit Care Med; 2024 Jul; 52(7):e365-e375. PubMed ID: 38501933
[TBL] [Abstract][Full Text] [Related]
18. Caring for patients with opioid use disorder in the hospital.
Donroe JH; Holt SR; Tetrault JM
CMAJ; 2016 Dec; 188(17-18):1232-1239. PubMed ID: 27647616
[No Abstract] [Full Text] [Related]
19. Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients.
Rahman N; Janardhanan A; Shikalgar S; Pirkhan MA; Canner J; Skipwith C; Noor-E-Alam M
Subst Use Misuse; 2024; 59(9):1275-1279. PubMed ID: 37950394
[TBL] [Abstract][Full Text] [Related]
20. Narrative review: buprenorphine for opioid-dependent patients in office practice.
Sullivan LE; Fiellin DA
Ann Intern Med; 2008 May; 148(9):662-70. PubMed ID: 18458279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]